시장보고서

상품코드

1592587

아시아태평양의 간질 시장 예측(-2030년) - 지역별 분석 : 유형별, 투여 경로별, 치료 유형별, 연령대별, 유통 채널별

Asia Pacific Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel

발행일: 2024년 09월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 146 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

아시아태평양의 간질 시장은 2022년 22억 92만 달러, 2030년까지 31억 4,344만 달러에 달할 것으로 예상되며, 2022년부터 2030년까지 4.6%의 CAGR을 기록할 것으로 예상됩니다.

단체의 인식 제고 프로그램 급증으로 아시아태평양의 간질 시장 성장 촉진

간질과 그 증상, 조기 진단의 중요성에 대한 인식이 높아지면서 의료 기관을 찾는 환자가 급증하고 있으며, Epilepsy Foundation, Epilepsy Society, American Epilepsy Society, Epilepsy Association of Central Florida of Central Florida와 같은 단체들은 간질에 대한 인식 개선에 중요한 역할을 하고 있습니다. 이러한 단체들의 참여로 진단율이 향상되고 간질 치료가 필요한 환자층이 확대되고 있습니다. 2023년 '간질의 보라색 날'을 맞아 인도 하이데라바드(Hyderabad)의 Aster Prime Hospitals는 Walkers Association of Krishna Kant Park, India와 함께 간질의 증상과 치료법에 대한 인식을 제고하기 위해 다양한 인식 개선 캠페인을 진행하고 있습니다. Association of Krishna Kant Park와 공동으로 인식 개선 활동을 진행했습니다. 이 세션에는 워커와 요가 수련생을 포함해 총 150명이 참가했습니다. 또한, Epilepsy Action Australia는 호주 간질 환자의 삶의 질을 향상시키기 위해 인식 개선, 교육, 필요한 기술 습득을 위한 다양한 도구와 서비스를 제공하고 있습니다. 이러한 노력과 인식 개선 캠페인은 간질 진단과 치료의 증가로 이어져 시장에 유익한 성장 기회를 제공하고 있습니다.

아시아태평양의 간질 시장 개요

아시아태평양의 간질 시장은 중국, 일본, 인도, 호주, 한국 및 기타 아시아태평양을 기준으로 분석됩니다. 세계보건기구(WHO)의 보고서에 따르면, 간질 유병률은 선진국보다 신흥국에서 더 높으며, 각각 6.1%와 5.0%를 차지합니다.

아시아태평양의 간질 시장 매출 및 2030년까지의 예측(금액)

아시아태평양의 간질 시장 세분화

아시아태평양의 간질 시장은 유형, 투여 경로, 치료 유형, 연령대, 유통 채널 및 국가별로 분류됩니다.

유형별로 아시아태평양의 간질 시장은 진행성 근간대성 간질, 반사성 간질, 일반 간질, 기타로 분류되며, 2022년에는 일반 간질이 가장 큰 시장 점유율을 차지했습니다.

투여 경로에 따라 아시아태평양의 간질 시장은 경구, 비경구, 기타로 분류되며, 2022년 경구 부문이 가장 큰 시장 점유율을 차지했습니다.

치료 유형별로 아시아태평양의 간질 시장은 1세대 의약품, 2세대 의약품, 3세대 의약품으로 분류되며, 2022년에는 3세대 의약품 부문이 가장 큰 시장 점유율을 차지했습니다.

연령대를 기준으로 아시아태평양의 간질 시장은 성인과 어린이로 나뉘며, 2022년 시장 점유율은 성인 부문이 더 큽니다.

유통 채널에 따라 아시아태평양의 간질 시장은 병원 약국, 소매 약국, 기타로 분류됩니다. 병원 약국 부문이 2022년 가장 큰 시장 점유율을 차지했습니다.

국가별로는 아시아태평양의 간질 시장은 중국, 일본, 인도, 인도, 호주, 한국, 기타 아시아태평양으로 구분되며, 2022년 아시아태평양의 간질 시장 점유율은 중국이 독차지했습니다.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, H. Lundbeck AS는 아시아태평양의 간질 시장에서 활동하는 주요 기업입니다.

간질 치료 접근법 파이프라인 연구
- 세포 및 유전자 치료 접근법
- 캡슐화 세포 바이오 딜리버리(ECB) 시스템
- 간질에 대한 유전자 치료 임상 개요
  - 간질 임상 연구에 채용되고 있는 유전자 치료
  - 간질에 대한 바이러스 벡터 파이프라인 연구
  - 간질 비바이러스성 벡터 파이프라인 연구
  - 아데노 부속 바이러스(AAV)를 통한 신경조절 펩타이드 - 개요
  - 유전자 치료를 위한 신경영양 인자
  - 인간 간질 표현형에 대한 칼륨 채널
  - 효소 유도성 항간질제

제5장 아시아태평양의 간질 시장 : 주요 시장 역학

시장 성장 촉진요인
- 간질 유병률 상승
- 간질 치료제 개발에 대한 투자 증가
시장 성장 억제요인
- 제품 회수
시장 기회
- 단체에 의한 인식 제고 프로그램 급증
향후 동향
- 유망한 치료 접근법으로서의 유전자 치료
성장 촉진요인과 억제요인의 영향

제6장 간질 시장 : 아시아태평양의 분석

아시아태평양의 간질 시장

제7장 아시아태평양의 간질 시장 분석 : 유형별

진행성 근육 경련 간질
반사성 간질
전반 간질
기타

제8장 아시아태평양의 간질 시장 분석 : 투여 경로별

경구
비경구
기타

제9장 아시아태평양의 간질 시장 분석 : 치료 유형별

제1세대 의약품
제2세대 의약품
제3세대 의약품

제10장 아시아태평양의 간질 시장 분석 : 연령층별

성인
아동

제11장 아시아태평양의 간질 시장 분석 : 유통 채널별

병원 약국
소매 약국
기타

제12장 아시아태평양의 간질 시장 : 국가별 분석

아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양

제13장 업계 상황

간질 시장 성장 전략
유기적 성장 전략
무기적 성장 전략

제14장 기업 개요

Abbott Laboratories
Pfizer Inc
Eisai Co Ltd
UCB SA
LivaNova Plc
Novartis AG
Medtronic Plc
GSK Plc
H. Lundbeck AS

제15장 부록

ksm 24.11.27

The Asia Pacific epilepsy market was valued at US$ 2,200.92 million in 2022 and is expected to reach US$ 3,143.44 million by 2030; it is estimated to register a CAGR of 4.6% from 2022 to 2030.

Surge in Awareness Program Conducted by Organizations Boosts Asia Pacific Epilepsy Market

Growing awareness about epilepsy, its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Epilepsy Society, the American Epilepsy Society, and the Epilepsy Association of Central Florida play a crucial role in educating people about this disease. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy treatment. Numerous awareness campaigns are conducted by organizations worldwide to spread awareness regarding the condition and available treatment. In 2023, on the Purple Day of Epilepsy, Aster Prime Hospitals in Hyderabad (India), in collaboration with the Walkers Association of Krishna Kant Park, held an awareness activity. One hundred fifty participants in total, including walkers and yoga practitioners, attended this session. Additionally, in order to improve the quality of life for Australians living with epilepsy, Epilepsy Action Australia offers a variety of tools and services aimed at raising awareness, educating, and equipping individuals with the necessary skills. Thus, such initiatives and awareness campaigns result in an increase in epilepsy diagnoses and treatments, offering lucrative growth opportunities to the market.

Asia Pacific Epilepsy Market Overview

The Asia Pacific epilepsy market is analyzed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively.

Asia Pacific Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Epilepsy Market Segmentation

The Asia Pacific epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the Asia Pacific epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the Asia Pacific epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the Asia Pacific epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the Asia Pacific epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the Asia Pacific epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the Asia Pacific epilepsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Asia Pacific epilepsy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Pipeline Studies for Epilepsy Therapy Approaches

4.1 Pipeline Studies for Epilepsy Therapy Approaches
- 4.1.1 Cell and Gene Therapy Approaches
- 4.1.2 Encapsulated cell bio delivery (ECB) system
- 4.1.3 Gene Therapy for Epilepsy Clinical Overview
  - 4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
    - 4.1.3.1.1 Gene Supplementation - Overview
    - 4.1.3.1.2 Gene Modulation - Overview
    - 4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
    - 4.1.3.1.4 Neuropeptides - Overview
    - 4.1.3.1.5 Engineered Channels - Overview
    - 4.1.3.1.6 Endogenous Channels - Overview
  - 4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
  - 4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
    - 4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
    - 4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
  - 4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
  - 4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
  - 4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
  - 4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. Asia Pacific Epilepsy Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Prevalence of Epilepsy
- 5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
- 5.2.1 Recall of Products
5.3 Market Opportunities
- 5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
- 5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - Asia Pacific Analysis

6.1 Asia Pacific: Epilepsy Market

7. Asia Pacific Epilepsy Market Analysis - by Type

7.1 Overview
7.2 Progressive Myoclonic Epilepsy
- 7.2.1 Overview
- 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
- 7.3.1 Overview
- 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
- 7.4.1 Overview
- 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
- 7.5.1 Overview
- 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Epilepsy Market Analysis - by Route of Administration

8.1 Overview
8.2 Oral
- 8.2.1 Overview
- 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
- 8.3.1 Overview
- 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Epilepsy Market Analysis - by Treatment Type

9.1 Overview
9.2 First Generation Drugs
- 9.2.1 Overview
- 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
- 9.3.1 Overview
- 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
- 9.4.1 Overview
- 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Epilepsy Market Analysis - by Age Group

10.1 Overview
10.2 Adult
- 10.2.1 Overview
- 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
- 10.3.1 Overview
- 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. Asia Pacific Epilepsy Market Analysis - by Distribution Channel

11.1 Overview
11.2 Hospital Pharmacies
- 11.2.1 Overview
- 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
- 11.3.1 Overview
- 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
- 11.4.1 Overview
- 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. Asia Pacific Epilepsy Market - Country Analysis

12.1 Asia Pacific Epilepsy Market Overview
- 12.1.1 Asia Pacific: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
  - 12.1.1.1 China: Epilepsy Market Overview
  - 12.1.1.2 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.2.1 China: Epilepsy Market Breakdown, by Type
    - 12.1.1.2.2 China: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.2.3 China: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.2.4 China: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.2.5 China: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.3 Japan: Epilepsy Market Overview
  - 12.1.1.4 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.4.1 Japan: Epilepsy Market Breakdown, by Type
    - 12.1.1.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.4.4 Japan: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.5 India: Epilepsy Market Overview
  - 12.1.1.6 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.6.1 India: Epilepsy Market Breakdown, by Type
    - 12.1.1.6.2 India: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.6.3 India: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.6.4 India: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.6.5 India: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.7 Australia: Epilepsy Market Overview
  - 12.1.1.8 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.8.1 Australia: Epilepsy Market Breakdown, by Type
    - 12.1.1.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.8.4 Australia: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.9 South Korea: Epilepsy Market Overview
  - 12.1.1.10 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.10.1 South Korea: Epilepsy Market Breakdown, by Type
    - 12.1.1.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.10.4 South Korea: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.1.11 Rest of Asia Pacific: Epilepsy Market Overview
  - 12.1.1.12 Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.12.1 Rest of Asia Pacific: Epilepsy Market Breakdown, by Type
    - 12.1.1.12.2 Rest of Asia Pacific: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.1.12.3 Rest of Asia Pacific: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.1.12.4 Rest of Asia Pacific: Epilepsy Market Breakdown, by Age Group
    - 12.1.1.12.5 Rest of Asia Pacific: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
- 13.3.1 Overview
13.4 Inorganic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Abbott Laboratories
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Pfizer Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Eisai Co Ltd
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 UCB SA
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 LivaNova Plc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Novartis AG
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Medtronic Plc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 GSK Plc
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 H. Lundbeck AS
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners